The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1393686
Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: A real-world study in China
Provisionally accepted- 1 Department of Thoracic Surgery, Shandong Provincial Hospital, Jinan, Shandong Province, China
- 2 The Second People Hospital of Dezhou, Dezhou, Shandong, China
- 3 Department of Radiotherapy, The Second People Hospital of Dezhou, Dezhou, China
- 4 Changle County TMC Hospital, Weifang, China
- 5 Department of Minimally Invasive Tumor Therapy, Shandong Provincial Hospital, Jinan, Shandong Province, China
- 6 The Second Hospital of Shandong University, Jinan, China
Objectives: Programmed death-ligand 1 (PD-L1) is the only Food and Drug Administrationapproved biomarker for monitoring response to immune checkpoint inhibitor (ICI) therapy in patients with lung adenocarcinoma. Understanding the nuances of molecular phenotypes, clinical attributes, and PD-L1 expression levels in primary and metastatic lung adenocarcinoma may help predict response to therapy and assist in the clinical management of lung adenocarcinoma.Methods: A total of 235 primary and metastatic lesion specimens from patients with non-small cell lung cancer (NSCLC) an institution in Shandong, China were analyzed. PD-L1 expression was assessed by immunohistochemistry using the 22C3 antibody, and the molecular phenotype was determined by next-generation sequencing of 450 genes. The molecular phenotypes of the primary and metastatic lesions were compared.Results: Elevated PD-L1 expression was significantly associated with advanced and metastatic disease (P = 0.001). The distribution of PD-L1 expression varied based on the anatomical location, showing a higher frequency of elevated PD-L1 expression in distal metastases than in the primary tumor. Metastatic lesions exhibited a higher proportion of carcinogenic pathway gene alterations and a greater number of DNA damage-repair pathway gene alterations than the primary lesions. Notably, CDKN2A copy number deletions were more prevalent in metastatic lesions than in primary lesions. Clinical data stemming from research conducted at the Memorial Sloan Kettering Cancer Center revealed an association between the absence of CDKN2A expression and a poorer prognosis in stage I lung adenocarcinoma.Samples of metastatic tumors exhibited a higher proportion of elevated PD-L1 expression, a greater number of pathway alterations, and a higher occurrence of CDKN2A copy number deletions than primary samples. This highlights the importance of reinforcing the clinical management and follow-up of patients with CDKN2A deficiency, particularly within the subset of stage I lung adenocarcinoma.
Keywords: Lung Adenocarcinoma, gene mutation, PD-L1, Metastatic lesion, CDKN2A
Received: 18 May 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Chen, Yu, Qi, Li, Li, Meng, Shen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yang Yu, Department of Thoracic Surgery, Shandong Provincial Hospital, Jinan, 250021, Shandong Province, China
Youchao Qi, The Second People Hospital of Dezhou, Dezhou, Shandong, China
Guangxu Li, The Second People Hospital of Dezhou, Dezhou, Shandong, China
Ning Li, Department of Radiotherapy, The Second People Hospital of Dezhou, Dezhou, China
Fande Meng, Changle County TMC Hospital, Weifang, China
Rong Shen, Department of Minimally Invasive Tumor Therapy, Shandong Provincial Hospital, Jinan, 250021, Shandong Province, China
Wujie Wang, The Second Hospital of Shandong University, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.